
Releases
AbbVie Reports Nine-Year Outcomes for Venetoclax in CLL Treatment
Patients with previously untreated chronic lymphocytic leukemia (CLL) showed sustained long-term benefits from a fixed-duration regimen of venetoclax combined with obinutuzumab, according to final data from the Phase 3 CLL14 trial presented at the European Hematology Association 2026 Congress in Stockholm.




















